Magni Alberto, Agostoni Piergiuseppe, Bonezzi Cesare, Massazza Giuseppe, Menè Paolo, Savarino Vincenzo, Fornasari Diego
Italian College of General Practitioners and Primary Care, Via Del Sansovino 179, Florence, Italy.
Centro Cardiologico Monzino, IRCCS, Via Carlo Parea, 4, Milan, Italy.
Pain Ther. 2021 Dec;10(2):783-808. doi: 10.1007/s40122-021-00260-1. Epub 2021 Apr 19.
Osteoarthritis (OA) is a leading cause of disability among older adults worldwide. Treatment aims are to alleviate inflammatory pain and improve physical function through non-pharmacological and pharmacological interventions. Non-steroidal anti-inflammatory drugs (NSAIDs) are recommended as first-line therapy. However, selection is challenged by patient age, comorbidities and polypharmacy, and by the drug's benefit/risk balance, all of which together influence the risk of cardiovascular (CV), gastrointestinal (GI) and renal adverse events (AEs). While the efficacy profile of the various NSAIDs is delineated, the differences in their safety profile are not straightforward. This narrative review provides practical indications by a multidisciplinary Italian expert panel for general practitioners and specialists managing OA patients with chronic inflammatory pain; the goal is to maximize therapy efficacy while reducing untoward effects caused by inappropriate NSAID use. The discussion on the best approach to NSAIDs spanned the following topics: (1) patient evaluation: investigate pain origin, duration and components together with possible risk factors for CV, GI and renal AEs; (2) non-pharmacological interventions: the physiatrist provides a person-centered, holistic approach accounting for all patient aspects; (3) pharmacological interventions: patient profile and drugs' pharmacological properties affect NSAID selection, which drugs to be used in combination or to be avoided, formulation and therapy duration; (4) the pharmacologist's, general practitioner's and pain therapist's points of view; (5) NSAID safety: the individual baseline risk and the drug's safety profile are major determinants of CV, GI and renal risk; consider possible drug-drug interactions; (6) periodical re-evaluation of treatment response and adherence, using scales to assess pain and function.
骨关节炎(OA)是全球老年人残疾的主要原因。治疗目标是通过非药物和药物干预来减轻炎性疼痛并改善身体功能。非甾体抗炎药(NSAIDs)被推荐作为一线治疗药物。然而,患者年龄、合并症、多种药物联用以及药物的获益/风险平衡对NSAIDs的选择提出了挑战,所有这些因素共同影响心血管(CV)、胃肠道(GI)和肾脏不良事件(AEs)的风险。虽然各种NSAIDs的疗效已明确,但它们安全性方面的差异并不简单。这篇叙述性综述由一个多学科的意大利专家小组为管理患有慢性炎性疼痛的OA患者的全科医生和专科医生提供实用建议;目标是在减少不适当使用NSAIDs所导致的不良影响的同时,最大化治疗效果。关于NSAIDs最佳使用方法的讨论涵盖了以下主题:(1)患者评估:调查疼痛的起源、持续时间和构成因素以及CV、GI和肾脏AEs的可能危险因素;(2)非药物干预:物理治疗师提供以患者为中心的整体方法,考虑患者的所有方面;(3)药物干预:患者情况和药物的药理学特性影响NSAIDs的选择、哪些药物可联合使用或应避免使用、剂型和治疗持续时间;(4)药理学家、全科医生和疼痛治疗师的观点;(5)NSAIDs安全性:个体基线风险和药物的安全性概况是CV、GI和肾脏风险的主要决定因素;考虑可能的药物相互作用;(6)使用量表评估疼痛和功能,定期重新评估治疗反应和依从性。